A drug safety physician working on innovative development strategies for the treatment of high risk locally advanced cervical cancer within Merck’s highly successful KEYTRUDA oncology program. I also support clinical safety for external collaborations programs with AstraZeneca, Eisai and Moderna, on LYNPARZA, LENVIMA and the Individualized Neoantigen Therapy (INT) V940 in combination with KEYTRUDA. Previous extensive development experience in oncology (early stage snd metastatic triple negative breast cancer) and within the hepatology/ gastroenterology, neuroscience and Women’s Health therapeutic areas on diverse programs including non-alcoholic steatohepatitis, Alzheimer’s disease, anesthesiology and contraception as well as numerous postmarket products. Competencies include leading safety strategy and authoring of Mod 2.7.4 summaries of clinical safety with multiple successful global adult and pediatric submissions on the BRIDION and EMEND programs. Leadership competency as global risk management safety team lead for multiple programs. Highly competent in signal evaluation and characterization of risks. Proficiency in authoring and review of aggregate safety reports including DSURs,PSURs, national renewals, risk management plans, Reference Safety Information and study protocols. Scientific safety input for PASS studies and comprehensive understanding of safety signal evaluation of pooled safety data.Physician, UK trained. I have leveraged my 20 years of clinical experience as a primary care physician to help provide expert pharmacovigilance analysis.